Algeria Issues Alert for Counterfeit 'Escodyne' Drug Amidst Efforts to Secure Pharmaceutical Supply Chain
Image: Echorouk
Takeaway
The Escodyne counterfeit alert highlights the risks associated with Algeria's informal pharmaceutical market and the importance of supply chain security. Pharmaceutical companies operating in Algeria should prioritize compliance with the upcoming serialization and aggregation regulations to protect their brands and ensure patient safety. Investors should monitor the implementation of these regulations and assess their impact on the competitiveness of local manufacturers versus importers.
Algerian health authorities issued an urgent warning on March 10, 2026, regarding a counterfeit version of a painkiller called “Escodyne” circulating outside of official pharmacies. The Directorate of Health and Population (DSP) of the wilaya of Bordj Bou Arréridj initially raised the alarm, alerting healthcare institutions and pharmacists to the fraudulent medication. The National Union of Public Health Practitioners also circulated the alert. The National Union of Pharmacists (SNAPO) confirmed that the product is not distributed through the official pharmaceutical channels and is not dispensed in pharmacies in Algeria.
The counterfeit Escodyne is reportedly smuggled into Algeria and poses a significant health risk due to its unknown composition. The DSP warned that the drug, presented as being of Zionist origin, could lead to death within five days of consumption. The drug is presented as an analgesic used to relieve headaches. Health authorities emphasize that its real composition and potential side effects remain unknown, dramatically increasing the risks for individuals who may consume it. The product reportedly enters the country through clandestine routes, transiting through Jordan and Syria before being distributed through certain parallel networks.
This incident underscores Algeria's ongoing efforts to combat counterfeit drugs and secure its pharmaceutical supply chain. Algeria's pharmaceutical market is the second-largest in Africa, estimated at USD 4 billion. The market is characterized by a semi-regulated environment that emphasizes local production, particularly of generics, which constitute approximately 65% of the market. The Ministry of Health, Population and Hospital Reform (MSPRH) is the regulatory authority responsible for drugs. The National Agency for Pharmaceutical Products (ANPP), created on July 2, 2018, regulates medicines and other medical products. In August 2025, the ANPP announced a mandatory serialization and aggregation regulation set to take full effect on January 1, 2027, to enhance pharmaceutical supply chain security and combat counterfeit drugs.
The circulation of counterfeit drugs poses a threat to public health and undermines confidence in the healthcare system. Health professionals are urged to report any suspicious presence of the product and to raise awareness among patients about the dangers of using pharmaceutical products obtained through informal or unauthorized channels. Authorities warn that medicines obtained through informal channels may contain untested or unapproved substances, potentially leading to serious medical complications.
Algeria's commitment to strengthening its pharmaceutical industry and regulatory framework will be crucial in preventing future incidents of counterfeit drugs. The ANPP's mandatory serialization and aggregation regulation, set to take effect on January 1, 2027, is a significant step towards improving traceability and combating falsification. Continuous vigilance and collaboration between health authorities, pharmacists, and the public are essential to safeguard public health and prevent the distribution of counterfeit medicines.